Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SALMA: Sulfasalazine + Standard of Care in AML
NCT05580861Phase 2Recruiting
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- May 2023
- Primary completion
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of 5-aminosalicylic acid + sulphasalazine in acute myeloid leukemia (AML), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoints: Dose Limiting Toxicity at 42 days and Minimal Residual Disease-negative Complete Response. Started May 2023; status: recruiting.
02
Drugs
5-aminosalicylic acid + sulphasalazine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05580861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05580861.